| 5.385 -0.145 (-2.62%) | 12-08 13:09 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 6.84 | 1-year : | 7.99 |
| Resists | First : | 5.86 | Second : | 6.84 |
| Pivot price | 5.2  |
|||
| Supports | First : | 4.39 | Second : | 3.49 |
| MAs | MA(5) : | 5.39 |
MA(20) : | 5.07 |
| MA(100) : | 3.81 |
MA(250) : | 0 | |
| MACD | MACD : | 0.3 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 69.4 |
D(3) : | 67 |
| RSI | RSI(14): 63.1 |
|||
| 52-week | High : | 5.86 | Low : | 1.33 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CMPX ] has closed below upper band by 32.0%. Bollinger Bands are 27% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.75 - 5.78 | 5.78 - 5.81 |
| Low: | 5.41 - 5.44 | 5.44 - 5.47 |
| Close: | 5.48 - 5.54 | 5.54 - 5.59 |
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Mon, 08 Dec 2025
Here's Why Compass Therapeutics, Inc. (CMPX) is a Great Momentum Stock to Buy - Nasdaq
Sun, 07 Dec 2025
Compass Therapeutics announces public offering of common stock By Investing.com - Investing.com Nigeria
Thu, 04 Dec 2025
Compass Therapeutics (NASDAQ:CMPX) Now Covered by Analysts at Canaccord Genuity Group - MarketBeat
Wed, 03 Dec 2025
Citizens Initiates Coverage of Compass Therapeutics (CMPX) with Market Outperform Recommendation - Nasdaq
Wed, 03 Dec 2025
Compass Therapeutics (NASDAQ:CMPX) Trading Down 6% - Time to Sell? - MarketBeat
Wed, 03 Dec 2025
CMPX Analyst Rating Update: Citizens Initiates Coverage with Market Outperform | CMPX Stock News - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 178 (M) |
| Shares Float | 108 (M) |
| Held by Insiders | 10.9 (%) |
| Held by Institutions | 82.9 (%) |
| Shares Short | 16,610 (K) |
| Shares Short P.Month | 15,360 (K) |
| EPS | -0.45 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.17 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -23.5 % |
| Return on Equity (ttm) | -37.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.4 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -45 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | -12.04 |
| PEG Ratio | 0 |
| Price to Book value | 4.58 |
| Price to Sales | 0 |
| Price to Cash Flow | -21.38 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|